Regulatory Filings Next Step for Ariad's Ponatinib in CML
By Marie Powers
Tuesday, June 5, 2012
Ariad Pharmaceuticals Inc. used the American Society of Clinical Oncology's (ASCO) annual meeting in Chicago as its forum to confirm that the next steps for its investigational pan-BCR-ABL inhibitor, ponatinib, will be regulatory filings in the U.S. and Europe, expected in the third quarter.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.